The FDA announced that it approved Incyte (INCY) Corporation’s tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, FL.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Positive Buy Rating for Incyte Driven by Promising INCA33989 Trial Results and Favorable Safety Profile
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Video: Sarepta, Hinge Health among major pre-market movers
- Incyte’s Strategic and Financial Challenges Prompt Sell Rating Despite Promising Trial Data